Our results show that metformin and TQ treatments for 48 h decrease levels of p-NF-κB p65 in LAMA-84 cells sensitive and resistant to imatinib, as well as in primary CLL cells (Figures 4A,C). The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.